Sign up
Pharma Capital

Squarex looks to raise $20 mln to develop its drug to prevent cold sores

Squarex CEO Hugh McTavish joined Proactive Investors at the 11th Annual BioTech Showcase in San Francisco.

Squarex is a clinical stage pharmaceutical company developing a topical formulation to prevent recurrent cold sores and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2.

 

View full SQRE profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.